Use of selenium–silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men

The aim of this double-blind, placebo controlled clinical trial was to assess the effects of a combination of selenium and silymarin in men with lower urinary tract symptoms, benign prostatic hyperplasia and a prostate specific antigen (PSA) ≤2.5ng/ml. The volunteers were randomized to two groups: t...

Full description

Saved in:
Bibliographic Details
Published in:Phytomedicine (Stuttgart) 2013-12, Vol.21 (1), p.75-81
Main Authors: Vostalova, Jitka, Vidlar, Ales, Ulrichova, Jitka, Vrbkova, Jana, Simanek, Vilim, Student, Vladimir
Format: Article
Language:English
Subjects:
Aged
Care and treatment
Chemical properties
Diagnosis
Double-Blind Method
Drug Combinations
Health aspects
Humans
Lower Urinary Tract Symptoms - blood
Lower Urinary Tract Symptoms - drug therapy
Lower Urinary Tract Symptoms - etiology
Male
Middle Aged
Phytotherapy
Plant Extracts - pharmacology
Plant Extracts - therapeutic use
Prostate-specific antigen
Prostate-Specific Antigen - blood
Prostatic Hyperplasia - blood
Prostatic Hyperplasia - complications
Prostatic Hyperplasia - drug therapy
Selenium
Selenium - pharmacology
Selenium - therapeutic use
Serum PSA
Silybum marianum - chemistry
Silymarin
Silymarin - pharmacology
Silymarin - therapeutic use
Testosterone - blood
Trace Elements - pharmacology
Trace Elements - therapeutic use
Urinary symptoms
Urinary tract infections
Urination - drug effects
Urodynamic parameters
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this double-blind, placebo controlled clinical trial was to assess the effects of a combination of selenium and silymarin in men with lower urinary tract symptoms, benign prostatic hyperplasia and a prostate specific antigen (PSA) ≤2.5ng/ml. The volunteers were randomized to two groups: the first one (n=26) received 240μg selenium (in the form of yeast l-selenomethionine) plus 570mg silymarin daily for 6 months and the second (n=29) received placebo. Outcome measures were changes in the International Prostate Symptom Score (IPSS), bladder volume (V), urinary flow rate, ultrasound estimated postvoid residual urine volume (RV), serum PSA, testosterone and selenium levels, safety clinical biochemistry, hematology and oxidative stress parameters at baseline and on day 180. The results showed statistically significant differences (p
ISSN:0944-7113
1618-095X
DOI:10.1016/j.phymed.2013.07.018